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Abstract
The dose-delivery schedule of conventional chemotherapy, which determines its efficacy and
toxicity, is based on the maximum tolerated dose. This strategy has lead to cure and disease control
in a significant number of patients but is associated with significant short-term and long-term
toxicity. Recent data demonstrate that moderately low-dose chemotherapy may be efficiently
combined with immunotherapy, particularly with dendritic cell (DC) vaccines, to improve the
overall therapeutic efficacy. However, the direct effects of low and ultra-low concentrations on
DCs are still unknown. Here we characterized the effects of low noncytotoxic concentrations of
different classes of chemotherapeutic agents on human DCs in vitro. DCs treated with
antimicrotubule agents vincristine, vinblastine, and paclitaxel or with antimetabolites 5-aza-2-
deoxycytidine and methotrexate, showed increased expression of CD83 and CD40 molecules.
Expression of CD80 on DCs was also stimulated by vinblastine, paclitaxel, azacytidine,
methotrexate, and mitomycin C used in low nontoxic concentrations. Furthermore, 5-aza-2-
deoxycytidine, methotrexate, and mitomycin C increased the ability of human DCs to stimulate
proliferation of allogeneic T lymphocytes. Thus, our data demonstrate for the first time that in low
noncytotoxic concentrations chemotherapeutic agents do not induce apoptosis of DCs, but
directly enhance DC maturation and function. This suggests that modulation of human DCs by
noncytotoxic concentrations of antineoplastic drugs, i.e. chemomodulation, might represent a
novel approach for up-regulation of functional activity of resident DCs in the tumor
microenvironment or improving the efficacy of DCs prepared ex vivo for subsequent vaccinations.
Introduction
Chemotherapy is the treatment of choice for most
patients with inoperable and advanced cancers and more
than half of all people diagnosed with cancer receive
chemotherapy. Chemotherapy is also often used as neo-
adjuvant or adjuvant modality for preoperative or postop-
erative treatment, respectively [1]. The antineoplastic
chemotherapeutic agents belong to several groups accord-
ing to the mechanism of their action, which include anti-
microtubule and alkylating agents, anthracyclines,
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antimetabolites, topoisomerase inhibitors, plant alka-
loids, and others [2].
Based on pre-clinical experiments, the log-dose survival
curve model for cancer cell killing became the leading
model for chemotherapy dose calculation [3]. The dose-
delivery schedule of conventional chemotherapy, which
determines its efficacy and toxicity, is based on the maxi-
mum tolerated dose (MTD), i.e. the highest dose of a drug
that does not cause unacceptable side effects. This strategy
of MTD chemotherapy has lead to cure and disease con-
trol in a significant number of patients but is associated
with significant short-term and long-term toxicity and
complications, including myelosuppression, neutrope-
nia, trombocytopenia, increased risk of infection and
bleeding, gastrointestinal dysfunctions, arthralgia,
liver toxicity, and the cardiac and nervous system damage
[4-6].
Recent studies have shown that cytotoxic drugs used at
lower doses (10–33% of the MTD) and given more fre-
quently – low-dose metronomic chemotherapy or a
'lower' dose dense chemotherapy, may have the potential
for antitumor efficacy by inhibiting tumor angiogenesis
[7,8]. Although low-dose metronomic chemotherapy can
lead to a significant response rate and stable disease in cer-
tain patient populations, this approach can be associated
with chronic toxicity such as severe lymphopenia with
opportunistic infection [3]. Interestingly, moderately low-
dose chemotherapeutics, for instance anthracyclins, have
been recently reported to indirectly activate dendritic cells
(DCs) by inducing secretion of alarmin protein from
dying tumor cells [9,10]. DCs, the most powerful antigen-
presenting cells, play a key role in induction and mainte-
nance of antitumor immunity and are widely tested as
promising therapeutic cancer vaccines in multiple ongo-
ing clinical trials [11]. However, other studies demon-
strated that many chemotherapeutic drugs in
conventional or moderately low concentrations could
induce apoptosis of DCs, directly inhibit their maturation
and function, expression of co-stimulatory molecules,
suppress dendropoiesis, and polarize DC development in
vitro as well as in vivo in chemotherapy-treated patients
[12-19]. We have recently reported that several chemo-
therapeutic agents could directly modulate key signaling
pathways [20] and production of IL-12, IL-10, IL-4, and
TNF-α [21] in murine DCs without inducing apoptotic
death of DCs when used in ultra-low noncytotoxic con-
centrations. Further investigation of this phenomenon,
which can be termed chemomodulation, revealed that cer-
tain chemotherapeutic agents from different groups in
low noncytotoxic concentrations directly up-regulated
maturation, expression of co-stimulatory molecules, and
processing and presentation of antigens to antigen-spe-
cific T cells by murine DCs [22]. Although indirect activa-
tion of human DCs by signals expressed on or released by
dying tumor cells due to chemotherapy, such as calreticu-
lin, heat-shock proteins, HMGB1, alarmin, and uric acid,
can be predicted [23-25], it is still unclear whether chem-
otherapeutic agents in noncytotoxic concentrations might
directly modulate the activity of human DCs.
Recent data demonstrate that administration of chemo-
therapeutic agents in conventional or low doses might sig-
nificantly attenuate the antitumor potential of DC
vaccines. For instance, gemcitabine increased survival of
mice treated with DC-based vaccines in a pancreatic carci-
noma model [26]. In murine fibrosarcoma model, com-
bined treatment of paclitaxel chemotherapy and the
injection of DCs led to complete tumor regression, in con-
trast to only partial eradication of the tumors with chem-
otherapy or DCs alone [27]. We have recently reported
that low-dose paclitaxel markedly up-regulates antitumor
immune responses in mice bearing lung cancer and
treated with DC vaccines [28]. Given the fact that DC vac-
cines combined with chemotherapy show therapeutic fea-
sibility [29] and are highly applicable for human
treatment [30], the goal of these studies was to determine
whether FDA-approved chemotherapeutic agents in low
noncytotoxic concentrations might directly affect viabil-
ity, maturation, and function of human DCs in vitro. Our
data demonstrate that certain chemotherapeutic agents in
low noncytotoxic concentrations do not alter viability of
human tumor cell lines or human DCs, but directly aug-
ment phenotypic maturation and antigen-presenting
potential of DCs. This suggests that chemomodulation,
i.e. modulation of DC function by noncytotoxic concen-
trations of antineoplastic drugs, might represent a novel
approach for improving the functional activity of DCs in
the tumor microenvironment and increasing the efficacy
of DC-based vaccination protocols.
Materials and methods
Antineoplastic chemotherapeutic agents
The following chemotherapeutic agents were used (with
the commercial brand names): the antimicrotubule
agents vinblastine (Velban), vincristine (Oncovin), and
paclitaxel (Taxol); the antimetabolites 5-aza-2-deoxycyti-
dine (Vidaza) and methotrexate (Rheumatrex, Trexall);
the alkylating agents cyclophosphamide (Cytoxan) and
mitomycin C (Mutamycin); the topoisomerase inhibitor
doxorubicin (Adriamycin); the platinum agents cisplatin
(Platinol) and carboplatin (Paraplatin); the hormonal
agents flutamide (Drogenil, Eulexin) and tamoxifen (Nol-
vadex); and the cytotoxic glycopeptide antibiotic bleomy-
cin (Blenoxane). 5-Bleomycin and 5-aza-deoxycytidin
were purchased from Sigma-Aldrich (St. Louis, USA) and
paclitaxel – from F.H. Faulding & Co. Ltd. (Mulgrave,
Autralia). All other drugs were purchased form Calbio-
chem (La Jolla, USA). All drugs were first dissolved in
endotoxin-free water following by appropriated dilutions
in culture medium as stated.Journal of Translational Medicine 2009, 7:58 http://www.translational-medicine.com/content/7/1/58
Page 3 of 10
(page number not for citation purposes)
Establishing noncytotoxic concentrations of 
chemotherapeutic drugs
Dose-dependent cytotoxicity of tested drugs was initially
tested on the following human tumor cell lines: LNCaP
prostate adenocarcinoma (ATCC, Manassas, VA, USA),
PCI-4B head and neck squamous cell carcinoma (UPCI,
Pittsburgh, PA, USA), and HCT-116 and HT-29 colon ade-
nocarcinomas (ATCC). Cells were cultured in RPMI 1640
medium supplemented with 10% FBS, 2 mM L-
glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential
amino acids, 10 mM HEPES, and 0.1 mg/ml gentamicin
(complete medium, CM) at 37°C and 5% CO2. All cell
lines were Mycoplasma-free.
The Effective Concentration (EC) of each of the tested
chemotherapeutic agent, i.e. the highest concentration of
a chemotherapeutic agent that does not inhibit the prolif-
erative activity of tumor cells, was determined by the
modified MTT cytotoxicity assay. Briefly, tumor cells (2 ×
104 cells/ml) were cultured in 96-well flat-bottom plates
(100 μl/well) for 24 h. After attachment, cells were treated
with different concentrations of tested drugs (0–100,000
nM) for 48 h. Then, the plates were centrifuged and 100
μl of supernatant in each well were replaced with 100 μl
of (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide bromide (MTT, Sigma) solution (1 mg/ml).
Cells were cultured for 3 h, the supernatants were
removed and 100 ul of dimethylsulphoxide (DMSO) was
added to each well to dissolve MTT. Plates were read at
540 nm (Wallac Microplate reader, Turku, Finland) and
EC values were estimated based on the MTT reduction to
formazan in living cells. Cells were considered resistant to
the treatment if corresponding EC values were greater
than 1,000 nM.
Generation of human monocyte-derived DCs
Human DCs were prepared from peripheral blood mono-
nuclear cells (PBMCs) of healthy donors as described ear-
lier [31]. Briefly, after gradient separation on
Lymphoprep-1077 (Axes Shield PoC, Oslo, Norway) and
lysis of red blood cells, PBMCs were resuspended in AIM-
V medium (Invitrogen Co., Carlsbad, USA) and seeded in
6-well plates (107cells/well). After incubation for 60 min
at 37°C, non-adherent cells were removed, and adherent
monocytes were cultured in CM with 1000 U/ml recom-
binant human (rh) GM-CSF and 1000 U/ml rhIL-4
(PeproTech, Rocky Hill, USA). Chemotherapeutic agents
were added to DC cultures on day 1, DCs were harvested
on day 6 and DC phenotype and function, as well as signs
of apoptosis were characterized as described below.
Evaluation of DC apoptosis induced by chemotherapeutics
Drug-induced apoptosis of DCs was assessed by the
Annexin V binding assay, as described earlier [20]. Cells
were stained with FITC-Annexin V (BD-PharMingen, San
Diego, USA) and propidium iodide (PI, 10 μg/ml, Sigma).
Cells undergoing early apoptosis were determined as the
percentage of Annexin V+/PI- cells by FACScan with Cell
Quest 1.0 software package (BD, San Diego, USA). Detec-
tion of early apoptotic events in DCs was shown to be a
more sensitive approach to estimate noncytotoxic concen-
trations of chemotherapeutic agents than evaluation of
both apoptotic/necrotic events as Annexin V+/PI+ cells.
Thus, the results are shown as the mean percentage of
Annexin V+/PI- cells ± SEM.
Analysis of DC phenotype
Control non-treated and drug-treated DCs were washed in
PBS containing 0.1% BSA and analyzed by flow cytometry
as described earlier [32]. Monoclonal antibodies (BD-
Pharmingen) against human HLA-DR, HLA-ABC, CD83,
CD80, CD86, CD40, and CD1a conjugated with FITC or
PE were added to cells and incubated for 30 minute at
4°C. Murine FITC-IgG and PE-IgG were used as isotype
controls. Data analysis was performed using the Cel-
lQuest and WinMDI software and the results were
expressed as the percentage of positive cells or Mean Flu-
orescent Intensity (MFI).
Mixed leukocyte reaction (MLR)
Functional activity of DCs was assessed by measuring
their ability to stimulate proliferation of allogeneic T lym-
phocytes isolated from PBMCs of healthy volunteers [33].
Drug-treated and control DCs were co-cultured with allo-
geneic nylon wool-enriched T lymphocytes in a 96-round
bottom plates at different DC:T ratios (1:1, 1:3, 1:10, 1:30,
1:100, and 1:300) in 200 μl of CM for 96 h. Cultures were
pulsed with 3H-thymidine (1 μCi/well, Perkin Elmer, Bos-
ton, USA) for 4 h and harvested onto glass fiber filters GF/
C (Wallac, Turku, Finland). Uptake of 3H-thymidine was
assessed on liquid scintillation counter (Wallac 1205
Betaplate) and the results were expressed as count per
minute (cpm).
Statistical analysis
The effect of tested drugs on tumor cells and DCs viability
was analyzed by Student's t test comparing each group
with untreated controls. Alterations in DC phenotype and
MLR activity were evaluated by Kruskal-Wallis one-way
ANOVA. The differences were considered significant when
error probability was less than 5% (p < 0.05). All statisti-
cal analyses were done using SigmaPlot 11.0 software
(SSNS).
Results
Noncytotoxic concentration of chemotherapeutic agents
Determination of noncytotoxic concentrations of 13 anti-
neoplastic drugs was done using four human tumor cell
lines by examining viability of cells treated with a drug in
different concentrations (0 – 100 μM). The highest con-Journal of Translational Medicine 2009, 7:58 http://www.translational-medicine.com/content/7/1/58
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centrations that do not inhibit tumor cell proliferation are
shown in Table 1 as the results of three independent
experiments. As can be seen, the effective concentrations
of tested agents differ for different tumor cell lines. For
instance, prostate cancer cells showed the highest resist-
ance to tested cytotoxic agents, while colon cancer cell
lines were relatively sensitive. Interestingly, both LNCaP
and PCI-4B cell were resistant to the effects of platinum
and hormonal agents. These results thus allowed exclu-
sion of five chemotherapeutic agents (cyclophosphamide,
cisplatin, carboplatin, flutamide, and tamoxifen) from
further analysis since these agents did not display a dose-
dependent cytotoxicity against selected tumor cell lines.
The ability of the remaining chemotherapeutic agents to
induce dose-dependent cytotoxic effect on human DCs
was evaluated in the next series of experiments.
DC response to the cytotoxic effect of chemotherapeutics
cannot be determined in the MTT assay because many
drugs in low and moderately low concentrations induce
activation of mitochondrial dehydrogenases in DCs,
which makes the analysis of dose-dependent cell viability
unfeasible. Therefore, we utilized Annexin V/PI staining
to establish noncytotoxic concentrations of eight chemo-
therapeutic agents for human DCs. Cells were treated with
a range of concentrations of cytotoxic agents (0–100 nM)
and the levels of apoptosis were assessed by Annexin V/PI
binding assay (Table 2). The results showed that the EC
values of tested drugs for the tumor cell lines were similar
to or lower than the EC values for DCs, suggesting that
tumor cells are more sensitive to tested substances than
DCs are. These data allowed the establishment of concen-
trations of chemotherapeutic drugs that are nontoxic for
tumor cell lines and DCs. To ensure that no cytotoxicity is
induced in experiments determining the effects of drugs
on DC phenotype and function in vitro, we used the con-
centrations of drugs that are even 5–10-fold lower than
those established in Tables 1 and 2.
Chemomodulation of DC phenotype by low noncytotoxic 
concentrations of chemotherapeutic agents
Phenotype of control and drug-treated DCs was analyzed
by the expression of HLA-DR, CD83, CD80, CD86, CD40,
and CD1a molecules. The results in Table 3 show that vin-
Table 1: Noncytotoxic concentrations of chemotherapeutic agents (MTT assay)
Chemotherapeutic agents EC*
LNCaP
EC
PCI-4B
EC
HCT-116
EC
HT-29
Antimicrotubule agents
Vinblastine (Velban) 100 nM 10 nM ND ND
Vincristine (Oncovin) 100 nM 0.1 nM ND ND
Paclitaxel (Taxol) 10 nM 0.1 nM 0.5 nM 5 nM
Antimetabolites
5-azacytidine (Vidaza) 100 nM 50 nM ND ND
Methotrexate (Rheumatrex, Trexall) 5 nM 5 nM 0.5 nM ND
Alkylating agents
Cyclophosphamide (Cytoxan) Resistant** 50 nM 50 nM ND
Mitomycin C (Mutamycin) 500 nM 50 nM ND ND
Topoisomerase inhibitors
Doxorubicin (Adriamycin) 100 nM 50 nM 5 nM 5 nM
Platinum agents
Cisplatin (Platinol) Resistant Resistant ND ND
Carboplatin (Paraplatin) Resistant Resistant ND ND
Hormonal agents
Flutamide (Drogenil, Eulexin) Resistant Resistant ND ND
Tamoxifen (Nolvadex) 1000 nM Resistant ND ND
Others
Bleomycin (Blenoxane) 100 nM 100 nM ND ND
*, EC, Effective concentration – the maximal concentration of a chemotherapeutic agent that caused no inhibition of tumor cell activity in the MTT 
assay.
**, Cells were considered resistant to the treatment when the EC value was greater than 1,000 nM.
LNCaP, human prostate cancer cell line; PCI-4B, human head and neck squamous cell carcinoma cell line; HCT-116 and HT-29, human colon cancer 
cell lines; MTT, (3-(4,5-Dimmethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reduction assay; ND, not determined.Journal of Translational Medicine 2009, 7:58 http://www.translational-medicine.com/content/7/1/58
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cristine, vinblastine, paclitaxel, mitomycin C, and doxoru-
bicin markedly (25–70%) increased the expression of
CD83 molecules on DC surface, suggesting up-regulation
of DC maturation. The results in Table 3, calculated from
MFI values, are expressed as the percentage of MFI
increase in drug-treated DCs in comparison to MFI values
in control untreated DCs. Increase in expression of an
assessed marker of greater than 30% was considered to be
biologically significant and was examined with the statis-
tical analysis. Although the results were donor-dependent,
the up-regulation of CD83 expression on DCs treated
with vinblastine, paclitaxel, and doxorubicin was statisti-
cally significant (p < 0.05). For instance, vinblastine ele-
vated expression of CD83 on DCs in 2.5-fold increasing it
from 3.37 MFI to 8.16 MFI in healthy Donor 1. Further-
more, DCs treated with antimicrotubule agents vinblast-
ine, vincristine and paclitaxel, and antimetabolites
azacytydine and methotrexate displayed enhanced expres-
sion of CD40 molecules (up to 30–50%, p < 0.05). For
instance, in Donor 1, methotrexate doubled expression of
CD40 rising it from 12.44 MFI to 20.19 MFI, while in
donor 3 expression of CD40 was increased from 90.04
MFI to 130.11 MFI. Interestingly, expression of HLA-DR
and CD86 molecules on DCs was not markedly altered by
tested chemotherapeutic agents in low noncytotoxic con-
centrations, although in donor 3, vinblastine and azacyti-
dine up-regulated expression of MHC class II molecules
up to 50%. Altogether, these results demonstrate that, in
spite of the fact that stimulation of expression of MHC
class II and co-stimulatory molecules on DCs was drug-
and donor-dependent, many of the tested chemothera-
peutic drugs were able to directly up-regulate maturation
of human DCs in vitro.
FACScan analysis of the percentage of positive cells con-
firmed these results. For instance, Figure 1A demonstrates
that paclitaxel (5 nM) increased the expression of HLA-DR
on CD83+ DCs up to 155%, while bleomycin (1 nM) had
no effect. Figure 1B represents the results of CD40 expres-
sion on control and drug-treated DCs and shows that
methotrexate (5 nM) doubled the percentage of CD83+
DCs expressing CD40, while the effect of bleomycin (1
nM) was neglected. These data were reproduced in three
independent studies.
Thus, these results demonstrate that selected chemothera-
peutic drugs, including paclitaxel, methotrexate, vincris-
tine, and doxorubicin, in low noncytotoxic
concentrations may directly up-regulate phenotypic mat-
uration of human DCs in vitro. This raised the question
whether these chemotherapeutic agents in low concentra-
tions might directly affect antigen-presenting function of
DCs, which is known to be coupled with DC maturation.
Chemomodulation of antigen-presenting function of DCs 
by chemotherapeutic agents in low noncytotoxic 
concentrations
The overall ability of DCs to present antigens is com-
monly tested by the allogeneic MLR assay [34]. The results
of evaluation of the ability of control and drug-treated
DCs to induce allogeneic T cell responses are shown in
Figure 2. As demonstrated, introduction of low noncyto-
toxic concentrations of chemotherapeutics to DC cultures
did not decrease the ability of DCs to induce proliferation
of allogeneic T cells. Rather, we revealed that several
agents stimulated antigen-presenting function of DCs in
the MLR assay: DCs treated with 5-aza-2-deoxycytidine
(10 nM), methotrexate (5 nM) and mitomycin C (50 nM)
showed increased potential to stimulate T cell prolifera-
Table 2: Sensitivity of human DCs to the cytotoxic effects of 
antineoplastic chemotherapeutic agents in vitro
Chemotherapeutic agent
(concentration, nM)
Apoptosis of DCs
(% ± SEM)
vinblastine (50) 3.2 ± 0.9
vinblastine (10) 1.1 ± 1.3
vinblastine (1) 0.9 ± 0.3
vinblastine(0.1) -0.6 ± 0.3
vincristine (50) 6.5 ± 2.1
vincristine (10) 3.3 ± 1.9
vincristine (1) 0.5 ± 0.6
vincristine (0.1) -0.6 ± 0.9
paclitaxel (25) 4.9 ± 2.3
paclitaxel (5) 2.2 ± 0.7
paclitaxel (1) 2.2 ± 0.4
paclitaxel (0.1) 0.1 ± 0.3
5-aza-2deoxycitidine (25) 7.4 ± 3.3
5-aza-2deoxycitidine (5) 0.8 ± 0.8
methotrexate (25) 3.9 ± 1.1
methotrexate (5) 0.8 ± 0.6
methotrexate (1) 0.3 ± 0.4
mitomycin C (25) 1.3 ± 1.4
mitomycin C (5) -0.9 ± 0.4
doxorubicin (100) 5.5 ± 0.9
doxorubicin (25) 3.4 ± 0.3
doxorubicin (5) 0.6 ± 1.8
Analysis of DC survival was carried out by flow cytometry after the 
staining with FITC-Annexin V and propidium iodide. DCs were 
treated with the cytotoxic agents for 48 h and analyzed by FACScan 
after staining. The background staining of control non-treated DC 
value was subtracted from experimental results. The results are 
express as the mean percentage of Annexin+PI- cells ± SEM of 3 
independent assays. Student's t test was applied to compare the 
results of the treatment with different drug concentrations with 
control non-treated DC values in order to determine Effective 
Concentration (EC), i.e. the highest concentration of a 
chemotherapeutic agent that does not induce apoptosis in DCs.Journal of Translational Medicine 2009, 7:58 http://www.translational-medicine.com/content/7/1/58
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Table 3: Chemomodulation of phenotypic maturation of human DCs in vitro
Marker HLA-DR CD83 CD80 CD86 CD40 CD1a
Agent
Vinblastine, 1 nM 25.0 ± 4.5 72.7 ± 10.1* 16.5 ± 13.1 2.9 ± 3.5 46.1 ± 3.1* 16.7 ± 0.9
Vincristine, 1 nM 10.7 ± 0.7 25.9 ± 4.9 1.6 ± 0.2 27.0 ± 22.0 52.7 ± 2.9* 19.4 ± 0.3
Paclitaxel, 5 nM 0.5 ± 3.1 30.2 ± 5.7* 5.4 ± 27.5 6.9 ± 3.2 29.3 ± 3.4* 6.0 ± 2.3
5-aza-2-deoxycytidine, 5 nM 29.1 ± 12.2 8.1 ± 4.2 50.2 ± 3.2* 2.4 ± 6.4 33.4 ± 6.9* 10.8 ± 4.3
Methotrexate, 5 nM 3.6 ± 2.2 2.1 ± 1.8 6.5 ± 3.6 6.2 ± 0.8 51.0 ± 6.5* 35.9 ± 5.7*
Mitomycin C, 50 nM 4.2 ± 2.7 25.0 ± 12.8 12.0 ± 22.2 3.4 ± 0.9 24.9 ± 12.3 32.1 ± 5.8*
Doxorubicin, 10 nM 4.7 ± 0.3 38.8 ± 4.3* 4.24 ± 5.9 3.1 ± 2.0 14.3 ± 6.8 5.3 ± 7.1
The results in Table 3, calculated from MFI values, are expressed as the percentage of MFI increase in drug-treated DCs in comparison to MFI in 
untreated DCs. Increase in any marker expression of greater than 30% was considered to be biologically significant and was analyzed for statistical 
significance of changes. Data represent the mean ± SEM from 3 independent experiments utilizing cells from 3 different healthy donors. *, p < 0.05 
(ANOVA, N = 3).
Chemomodulation of phenotype of human DCs by antineoplastic chemotherapeutic agents in low noncytotoxic concentra- tions Figure 1
Chemomodulation of phenotype of human DCs by antineoplastic chemotherapeutic agents in low noncyto-
toxic concentrations. DCs were generated from monocyte isolated from PBMC of healthy volunteers by culturing mono-
cytes in complete medium supplemented with GM-CSF and IL-4 as described in Materials and Methods. Chemotherapeutic 
agents were added to DC cultures for 48 h and DCs were harvested on day 6 for phenotypic analysis. Results of a representa-
tive experiment assessing the co-expression of CD83 and HLA-DR (A) or CD40 (B) on control and drug-treated DCs are 
shown. Similar data were obtained in three independent experiments using PBMC from three different donors. Control, non-
treated DCs.
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tion in comparison with untreated control DCs. For
instance, in the optimal DC:T cell ratio 1:3, T cell prolifer-
ation reached 48,093 ± 2,010 cpm, 42,198 ± 769 cpm,
and 40,428 ± 1,423 cpm when DCs were pre-treated with
5-azacytidine, methotrexate, and mitomycin C, respec-
tively (p < 0.05 versus 32,362 ± 1,124 cpm for control
DCs, ANOVA, N = 4). Thus, these results suggest that cer-
tain chemotherapeutic drugs in low nontoxic concentra-
tion were able to directly up-regulate antigen-presenting
function of human DCs in vitro.
Discussion
Antineoplastic chemotherapy agents act on highly prolif-
erating tumor cells; however, proliferation of immune
cells might be also affected by a variety of cytotoxic drugs.
The suppression of the immune response by conventional
high-dose chemotherapy may support tumor escape
allowing the proliferation of chemoresistant variants of
tumor cells. Decreasing the dose of chemotherapeutics
has been suggested as an alternative approach, which
might limit many side effects of conventional cytotoxic
chemotherapy [35,36]. In addition, low-dose chemother-
apy might support the development of immune responses
against the tumor [37,38], although direct immune mod-
ulating activities of chemotherapeutic agents was not
explored yet. Understanding the effect of low-dose non-
toxic chemotherapy on the immune system is fundamen-
tal for improving the efficacy of immunotherapy in
combinatorial anticancer modalities.
In the present study, we showed for the first time that the
treatment of human DCs with different chemotherapeutic
agents in very low concentrations did not induce apopto-
sis of DCs, but stimulated DC maturation and increased
the ability of DCs to induce T cell proliferation. Our
results are in agreement with the in-vivo data reported by
Liu et al. [38] and might explain their observation that a
single administration of low-dose cyclophosphamide (50
mg/kg) in tumor-bearing mice prior to immunization
with DCs increased the frequency of IFN-γ secreting anti-
tumor CTLs. In the present study, we revealed that treat-
ment of DCs with mitomycin C, which also belongs to the
family of alkylating agents as cyclophosphamide does,
increased the ability of DCs to stimulate T cell prolifera-
tion. Interestingly, Jiga et al. observed that mitomycin C,
when used in concentrations that are significantly higher
(up to 6.0 μM) than those used in our studies, induced the
generation of tolerogenic DCs, which expressed low levels
of CD80 and CD86 and displayed low activity in the MLR
assay [16]. Our data also differ from the results of Chao et
al., who reported that doxorubicin and vinblastine signif-
icantly reduced the antigen-presenting function of human
DCs assessed in the MLR assay [12]. However, the concen-
trations of drugs used in that study were at least 25 times
higher for doxorubicin and 20,000 times higher for vin-
blastine then the concentrations we used in our experi-
ments. Therefore, DCs might demonstrate diverse
immunobiological responses to chemotherapy that
depend on the concentration of a chemotherapeutic
agent. Our data support this conclusion and demonstrate
that cytotoxic agents might display unusual properties
when used in ultra-low noncytotoxic concentrations: they
may stimulate functional activation of human DCs in
vitro.
The concentrations of chemotherapy agents used in our
studies are lower than the therapeutic concentrations
achieved in plasma in patients during chemotherapy,
although the significance of this comparison is quite lim-
ited due to complex pharmacodynamics of many drugs in
vivo. For instance, in patients receiving three consecutive
3-weekly courses of conventional paclitaxel at dose levels
of 135, 175, and 225 mg/m2, the plasma levels of the drug
reached 10.2 ± 1.34 to 15.5 ± 1.38 and 31.8 ± 5.40 μM
[39]. However, administration of low-dose metronomic
vinblastine (1 mg/m2  IV 3×/wk) in cancer patients
resulted in peak plasma concentrations of vinblastine
reaching 30 μg/l, i.e. ~37 nM [40]. To the best of our
knowledge, this constitutes the first report of low-dose
Up-regulation of antigen-presenting function of human DCs  treated with chemotherapeutic agents in low noncytotoxic  concentrations Figure 2
Up-regulation of antigen-presenting function of 
human DCs treated with chemotherapeutic agents 
in low noncytotoxic concentrations. Human monocyte-
derived DCs were treated with low nontoxic concentrations 
of selected drugs for 48 h. Cells were collected on day 6 and 
co-cultured with allogeneic nylon-wool purified T lym-
phocytes for 96 h. Cell cultures were pulsed with 3H-thymi-
dine for 4 h prior to harvesting and counting in a liquid 
scintillation counter. The drugs were used in the following 
concentrations: vinblastine and vincristine, 1 nM; paclitaxel, 
azadeoxycytidine, and methotrexate, 5 nM; doxorubicin, 10 
nM; mitomycin C, 50 nM. The mean ± SEM. *, p < 0.05 
(ANOVA, N = 4). Control, non-treated DCs.
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vinblastine pharmacokinetics in any human population.
These nanomolar concentrations were slightly higher
than the concentrations used in our studies, but were in a
close range. Interestingly, in the abovementioned group
of patients treated with low-dose metronomic vinblastine,
the plasma concentrations measured were above the pre-
clinically validated target concentration of 1 pM, as was
estimated based on the effect of vinblastine on angiogen-
esis in vivo in the chick embryo chorioallantoic mem-
brane (CAM) model [41].
The dose-dependent immunomodulating activities of
chemotherapeutic agents were also reported for other
immune cell populations. For instance, cyclophospha-
mide might not only decrease the number and prolifera-
tion of regulatory T cells (Treg), but also down regulate
their function [42]. Recently, Banissi et al. reported that
administration of low dose of temozolomide in glioblas-
toma-bearing rats significantly decreased the number of
Treg, whereas a high-dose regimen did not modify the
number of these cells [43]. Furthermore, Tanaka et al.
have used an experimental model to study a combination
of intratumoral injection of DCs with chemotherapeutic
agents where MC38-bearing mice were treated i.p. with 5-
fluoracil and cisplatin [44]. The authors observed that the
high doses of drugs (100 mg/kg 5-FU + 1.0 mg/kg CIS),
which were needed for inhibiting tumor growth, were also
lethal for all animals. While the lower doses of drugs (10
mg/kg 5-FU+ 0.1 mg/kg CIS) only delayed the tumor
growth during the first week, the combination of low-
dose chemotherapy with intratumoral inoculation of DCs
completely abrogated tumor growth in mice. Similarly,
we have recently reported that a single administration of
low-dose paclitaxel prior to intratumoral DC vaccine in
3LL-bearing mice caused a significantly stronger inhibi-
tion of tumor growth than either therapy alone [28]. Low
nontoxic concentrations of paclitaxel were not only able
to up-regulate function of murine DCs, but protected DCs
from tumor-induced inhibition [28]. Thus, although
moderately low doses of certain chemotherapeutic agents
could indirectly support antitumor immunity by blocking
Treg- or myeloid-derived suppressor cells (MDSC)-medi-
ated immune tolerance or activating DCs by "danger" sig-
nals released from dying tumor cells [23,36,45], it seems
that the use of lower doses of cytotoxic drugs, i.e. low-dose
noncytotoxic chemomodulation, might represent a new
approach for altering immunogenicity of the tumor
microenvironment and improving the antitumor poten-
tial of both resident DCs and exogenous DCs adminis-
tered as a vaccine.
The effects of methotrexate, paclitaxel, vincristine, and
vinblastine on maturation and activation of human DCs
additionally supports the feasibility of adjuvant chemo-
modulation or chemo-immunotherapy, since these drugs
were able to increase the level of expression of CD83,
CD80, and especially CD40 on DCs. CD40 is a phosphol-
ipoprotein belonging to the superfamily of type I TNF-
receptors that expressed on both normal host cells
(mainly DCs, B lymphocytes, macrophages and mast
cells) and some tumor cells [46]. Expression of CD40 on
DCs is essential for their interaction with T lymphocytes
and development of efficient Th1 responses [47]. Because
expression of CD40 on DCs, as well as CD40-mediated
DC function are suppressed during tumor progression
[48], its up-regulation by nontoxic chemotherapy should
support the development of antitumor immunity in
tumor-bearing hosts. In addition, CD40 ligation protects
human and murine DCs from tumor-induced apoptosis
by inducing expression of anti-apoptotic proteins from
the Bcl-2 family [32,49,50].
Increased expression of CD40 molecules on DCs treated
with methotrexate and mitomycin C is in agreement with
their increased ability to stimulate T cell proliferation in
the MLR assay (Figure 2). However, this correlation was
not seen for other tested drugs, suggesting the importance
of other mechanisms involved in up-regulation of anti-
gen-presenting function of DCs by chemomodulation. In
fact, in the murine models, we have recently revealed that
the ability of DCs treated with paclitaxel, methotrexate,
doxorubicin, and vinblastine to increase antigen presenta-
tion to antigen-specific T cells was abolished in DCs gen-
erated from IL-12 knockout mice, indicating that up-
regulation of antigen presentation by DCs is IL-12-
dependent and mediated by the autocrine or paracrine
mechanisms. At the same time, IL-12 knockout and wild
type DCs demonstrated similar capacity to up-regulate
antigen presentation after their pretreatment with low
concentrations of mitomycin C and vincristine, suggest-
ing that these agents do not utilize IL-12-mediated path-
ways in DCs for stimulating antigen presentation [22].
In summary, our results show for the first time that several
FDA-approved antineoplastic chemotherapeutic agents in
low noncytotoxic concentrations do not reduce longevity
and activity of normal human DCs; conversely, this treat-
ment, i.e. chemomodulation, promotes maturation of
DCs and their antigen-presenting activity. These data thus
provide evidence that chemomodulation might be used
for the generation of effective DC vaccines ex vivo and for
improving function of resident DCs in vivo in the diseases
associated with inhibited functionality of conventional
DCs, e.g., cancer. These results also support further studies
to evaluate the feasibility and clinical applicability of
using chemomodulation of human DCs in vivo.
Conclusion
Our data demonstrate for the first time that in low noncy-
totoxic concentrations chemotherapeutic agents do notJournal of Translational Medicine 2009, 7:58 http://www.translational-medicine.com/content/7/1/58
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induce apoptosis of human DCs, but directly enhance DC
maturation and function. This suggests that modulation
of human DCs by noncytotoxic concentrations of antine-
oplastic drugs, i.e. chemomodulation, represents a novel
approach for up-regulation of functional activity of resi-
dent DCs in the tumor microenvironment or improving
the efficacy of DCs prepared ex vivo for subsequent vacci-
nations.
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